Yuval Freifeld, Yin Xi, Niccolo Passoni, Solomon Woldu, Brad Hornberger, Kenneth Goldberg, Aditya Bagrodia, Ganesh Raj, Vitaly Margulis, Jeffrey A Cadeddu, Yair Lotan, Franto Francis, Ivan Pedrosa, Claus G Roehrborn, Daniel N Costa
OBJECTIVES: To determine the implications of different prostate sampling schemes on the diagnosis of clinically significant prostate cancer (csPCA, ISUP group 2-5) and clinically insignificant prostate cancer (ciPCA, ISUP group 1) in men with abnormal multiparametric magnetic resonance imaging (mpMRI) undergoing MRI-transrectal ulrasound fusion targeted biopsies. MATERIALS AND METHODS: This is a retrospective analysis of a cohort including all men who had a single lesion on mpMRI of the prostate performed between January 2016 and June 2017...
January 2019: Urologic Oncology